Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results